{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:33:18Z","timestamp":1786408398982,"version":"build-2736575974"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.phrs.2021.105943","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T02:24:22Z","timestamp":1634351062000},"page":"105943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Cardiovascular angiotensin II type 1 receptor biased signaling: Focus on non-Gq-, non-\u03b2arrestin-dependent signaling"],"prefix":"10.1016","volume":"174","author":[{"given":"Anastasios","family":"Lymperopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana I.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Cora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Sizova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105943_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.ircmb.2018.02.007","article-title":"Biased agonism\/antagonism of cardiovascular GPCRs for heart failure therapy","volume":"339","author":"Desimine","year":"2018","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.phrs.2021.105943_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2015.05.019","article-title":"GPCR signaling and cardiac function","volume":"763","author":"Capote","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105943_bib3","first-page":"1209","article-title":"Current and future G protein-coupled receptor signaling targets for heart failure therapy","volume":"7","author":"Siryk-Bathgate","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2021.105943_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/CIRCRESAHA.118.311403","article-title":"G-protein-coupled receptors in heart disease","volume":"123","author":"Wang","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2021.105943_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2021.105943_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3389\/fendo.2019.00519","article-title":"The role of \u03b2-arrestin proteins in organization of signaling and regulation of the AT1 angiotensin receptor","volume":"10","author":"Turu","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105943_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.beem.2018.02.003","article-title":"Novel mechanisms of G-protein-coupled receptors functions: AT1 angiotensin receptor acts as a signaling hub and focal point of receptor cross-talk","volume":"32","author":"T\u00f3th","year":"2018","journal-title":"Best. Pract. Res Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2021.105943_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ddr.21627","article-title":"Molecular signaling of G-protein-coupled receptor in chronic heart failure and associated complications","volume":"81","author":"Altamish","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.phrs.2021.105943_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0026-895X(24)23160-6","article-title":"Angiotensin II receptor coupling to phospholipase D is mediated by the betagamma subunits of heterotrimeric G proteins in vascular smooth muscle cells","volume":"55","author":"Ushio-Fukai","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105943_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cell.2016.07.004","article-title":"GPCR-G protein-\u03b2-arrestin super-complex mediates sustained G protein signaling","volume":"166","author":"Thomsen","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105943_bib11","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41467-017-01855-z","article-title":"G\u03b1i is required for carvedilol-induced \u03b21 adrenergic receptor \u03b2-arrestin biased signaling","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2021.105943_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41467-017-02661-3","article-title":"Lack of beta-arrestin signaling in the absence of active G proteins","volume":"9","author":"Grundmann","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105943_bib13","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1002\/jcb.26552","article-title":"Mechanoactivation of the angiotensin II type 1 receptor induces \u03b2-arrestin-biased signaling through G\u03b1i coupling","volume":"119","author":"Wang","year":"2018","journal-title":"J. Cell Biochem."},{"issue":"7","key":"10.1016\/j.phrs.2021.105943_bib14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cell.2020.11.014","article-title":"How GPCR phosphorylation patterns orchestrate arrestin-mediated signaling","volume":"183","author":"Latorraca","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105943_bib15","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.2174\/1381612811319170005","article-title":"Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers","volume":"19","author":"Imaizumi","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2021.105943_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320310370852","article-title":"Angiotensin II type 1 receptor blockers: class effects versus molecular effects","volume":"12","author":"Miura","year":"2011","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.phrs.2021.105943_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mce.2008.06.006","article-title":"Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism","volume":"302","author":"Van Liefde","year":"2009","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.phrs.2021.105943_bib18","doi-asserted-by":"crossref","first-page":"19288","DOI":"10.1074\/jbc.M602144200","article-title":"Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor","volume":"281","author":"Miura","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105943_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719868134","article-title":"The place of ARBs in heart failure therapy: is aldosterone suppression the key?","volume":"13","author":"Markan","year":"2019","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"7","key":"10.1016\/j.phrs.2021.105943_bib20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tips.2021.04.006","article-title":"Structural insights into ligand recognition and activation of angiotensin receptors","volume":"42","author":"Zhang","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2021.105943_bib21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/jpet.110.173005","article-title":"Selectively engaging \u03b2-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance","volume":"335","author":"Violin","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2021.105943_bib22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0026-895X(24)12327-9","article-title":"Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors","volume":"61","author":"Holloway","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105943_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1146\/annurev-biochem-060614-033910","article-title":"The molecular basis of G protein-coupled receptor activation","volume":"87","author":"Weis","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2021.105943_bib24","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2015.04.043","article-title":"Structural insights into the dynamic process of \u03b22-adrenergic receptor signaling","volume":"161","author":"Manglik","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2021.105943_bib25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cell.2018.12.005","article-title":"Angiotensin analogs with divergent bias stabilize distinct receptor conformations","volume":"176","author":"Wingler","year":"2019","journal-title":"Cell"},{"issue":"6480","key":"10.1016\/j.phrs.2021.105943_bib26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1126\/science.aay9813","article-title":"Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR","volume":"367","author":"Wingler","year":"2020","journal-title":"Science"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2021.105943_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cell.2018.10.050","article-title":"Beta-arrestin1 prevents preeclampsia by downregulation of mechanosensitive AT1-B2 receptor heteromers","volume":"176","author":"Quitterer","year":"2019","journal-title":"Cell"},{"issue":"6480","key":"10.1016\/j.phrs.2021.105943_bib28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1126\/science.aaz0326","article-title":"Molecular mechanism of biased signaling in a prototypical G protein-coupled receptor","volume":"367","author":"Suomivuori","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2021.105943_bib29","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1038\/s41467-021-25020-9","article-title":"Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design","volume":"12","author":"Lu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105943_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.109967","article-title":"Adrenal angiotensin II type 1 receptor biased signaling: The case for \"biased\" inverse agonism for effective aldosterone suppression","volume":"82","author":"Ferraino","year":"2021","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.phrs.2021.105943_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41594-017-0011-7","article-title":"Structure and dynamics of GPCR signaling complexes","volume":"25","author":"Hilger","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"48","key":"10.1016\/j.phrs.2021.105943_bib32","doi-asserted-by":"crossref","first-page":"28511","DOI":"10.1074\/jbc.270.48.28511","article-title":"Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation","volume":"270","author":"Noda","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105943_bib33","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1073\/pnas.0409532102","article-title":"Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling","volume":"102","author":"Kim","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"46","key":"10.1016\/j.phrs.2021.105943_bib34","doi-asserted-by":"crossref","first-page":"48255","DOI":"10.1074\/jbc.M406205200","article-title":"Stable interaction between beta-arrestin 2 and angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2","volume":"279","author":"Wei","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"44","key":"10.1016\/j.phrs.2021.105943_bib35","doi-asserted-by":"crossref","first-page":"16284","DOI":"10.1073\/pnas.0607583103","article-title":"Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes","volume":"103","author":"Rajagopal","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105943_bib36","doi-asserted-by":"crossref","first-page":"H1001","DOI":"10.1152\/ajpheart.00475.2012","article-title":"\u03b2-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury","volume":"303","author":"Kim","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2021.105943_bib37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCHEARTFAILURE.111.962571","article-title":"Cardiorenal actions of TRV120027, a novel \u00df-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure","volume":"4","author":"Boerrigter","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.phrs.2021.105943_bib38","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/eurheartj\/ehx196","article-title":"Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)","volume":"38","author":"Pang","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105943_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4330\/wjc.v11.i2.47","article-title":"Not all arrestins are created equal: therapeutic implications of the functional diversity of the \u03b2-arrestins in the heart","volume":"11","author":"Lymperopoulos","year":"2019","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.phrs.2021.105943_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/bs.pmbts.2018.07.003","article-title":"Arrestins in the cardiovascular system: an update","volume":"159","author":"Lymperopoulos","year":"2018","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.phrs.2021.105943_bib41","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tem.2015.09.001","article-title":"Emerging functional divergence of \u03b2-arrestin isoforms in GPCR function","volume":"26","author":"Srivastava","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2021.105943_bib42","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/HYPERTENSIONAHA.117.09817","article-title":"\u03b2-Arrestin2 improves post-myocardial infarction heart failure via sarco(endo)plasmic reticulum Ca2+-ATPase-dependent positive inotropy in cardiomyocytes","volume":"70","author":"McCrink","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105943_bib43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1161\/HYPERTENSIONAHA.113.02043","article-title":"Negative impact of \u03b2-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms","volume":"63","author":"Bathgate-Siryk","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2021.105943_bib44","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.jacc.2017.10.008","article-title":"Cardiac \u03b2arrestin2 improves contractility and adverse remodeling in heart failure, but is underexpressed in humans","volume":"70","author":"McCrink","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105943_bib45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4330\/wjc.v9.i3.200","article-title":"Angiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production: implications for heart failure therapy","volume":"9","author":"Lymperopoulos","year":"2017","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.phrs.2021.105943_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.497","article-title":"Adrenal \u03b2arrestin1 targeting for tobacco-associated cardiac dysfunction treatment: aldosterone production as the mechanistic link","volume":"7","author":"Solesio","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.phrs.2021.105943_bib47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/pr.109.002436","article-title":"Beyond desensitization: physiological relevance of arrestin-dependent signaling","volume":"62","author":"Luttrell","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2021.105943_bib48","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1073\/pnas.0811706106","article-title":"An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo","volume":"106","author":"Lymperopoulos","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105943_bib49","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jacc.2010.08.635","article-title":"Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels","volume":"57","author":"Lymperopoulos","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105943_bib50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0031-6997(25)06811-5","article-title":"Role of calcium and other mediators in aldosterone secretion from the adrenal glomerulosa cells","volume":"46","author":"Ganguly","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2021.105943_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2003.12.020","article-title":"Adrenocortical cell lines","volume":"228","author":"Rainey","year":"2004","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.phrs.2021.105943_bib52","doi-asserted-by":"crossref","first-page":"14335","DOI":"10.1038\/ncomms14335","article-title":"Arrestin-biased GPCR agonism induces acute catecholamine secretion through TRPC3 coupling","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105943_bib53","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/ijms21020574","article-title":"GRK2-mediated crosstalk between \u03b2-adrenergic and angiotensin II receptors enhances adrenocortical aldosterone production in vitro and in vivo","volume":"21","author":"Pollard","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105943_bib54","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1038\/srep08116","article-title":"Suppression of adrenal \u03b2arrestin1-dependent aldosterone production by ARBs: head-to-head comparison","volume":"5","author":"Dabul","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105943_bib55","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/j.jacc.2014.09.070","article-title":"Different potencies of angiotensin receptor blockers at suppressing adrenal \u03b2-Arrestin1-dependent post-myocardial infarction hyperaldosteronism","volume":"64","author":"Lymperopoulos","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105943_bib56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.phrs.2017.05.009","article-title":"Biased agonism\/antagonism at the AngII-AT1 receptor: implications for adrenal aldosterone production and cardiovascular therapy","volume":"125","author":"Maning","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105943_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/me.2007-0312","article-title":"Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state","volume":"22","author":"Miura","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105943_bib58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejphar.2008.05.010","article-title":"The human angiotensin AT(1) receptor supports G protein-independent extracellular signal-regulated kinase 1\/2 activation and cellular proliferation","volume":"590","author":"Hansen","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105943_bib59","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.phrs.2017.06.013","article-title":"Current topics in angiotensin II type 1 receptor research: focus on inverse agonism, receptor dimerization and biased agonism","volume":"123","author":"Takezako","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105943_bib60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/B978-0-12-381296-4.00002-6","article-title":"Assessment of inverse agonism for the angiotensin II type 1 receptor","volume":"485","author":"Akazawa","year":"2010","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.phrs.2021.105943_bib61","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1530\/JME-14-0125","article-title":"Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor","volume":"53","author":"Balakumar","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105943_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.226","article-title":"Structure-activity relationship study of angiotensin II analogs in terms of \u03b2-arrestin-dependent signaling to aldosterone production","volume":"4","author":"Valero","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.phrs.2021.105943_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114673","article-title":"Angiotensin II receptor type 1 - An update on structure, expression and pathology","volume":"192","author":"Eckenstaler","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"Pt A","key":"10.1016\/j.phrs.2021.105943_bib64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.phrs.2017.05.008","article-title":"AT1 receptor signaling pathways in the cardiovascular system","volume":"125","author":"Kawai","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"1\u20134","key":"10.1016\/j.phrs.2021.105943_bib65","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1152\/advances.2003.27.4.201","article-title":"Smooth muscle contraction and relaxation","volume":"27","author":"Webb","year":"2003","journal-title":"Adv. Physiol. Educ."},{"issue":"6","key":"10.1016\/j.phrs.2021.105943_bib66","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1161\/HYPERTENSIONAHA.114.05065","article-title":"Angiotensin II activates the RhoA exchange factor Arhgef1 in humans","volume":"65","author":"Carbone","year":"2015","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.phrs.2021.105943_bib67","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCRESAHA.108.188524","article-title":"ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells","volume":"104","author":"Wang","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2021.105943_bib68","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49374","article-title":"Myogenic vasoconstriction requires G12\/G13 and LARG to maintain local and systemic vascular resistance","volume":"8","author":"Chennupati","year":"2019","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.phrs.2021.105943_bib69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nm1666","article-title":"G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension","volume":"14","author":"Wirth","year":"2008","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.phrs.2021.105943_bib70","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1002\/jcb.26552","article-title":"Mechanoactivation of the angiotensin II type 1 receptor induces \u03b2-arrestin-biased signaling through G\u03b1i coupling","volume":"119","author":"Wang","year":"2018","journal-title":"J. Cell Biochem."},{"issue":"4","key":"10.1016\/j.phrs.2021.105943_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004965","article-title":"Intracellular angiotensin-II interacts with nuclear angiotensin receptors in cardiac fibroblasts and regulates RNA synthesis, cell proliferation, and collagen secretion","volume":"6","author":"Tadevosyan","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"11","key":"10.1016\/j.phrs.2021.105943_bib72","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1172\/JCI25330","article-title":"Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q\/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice","volume":"115","author":"Zhai","year":"2005","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.phrs.2021.105943_bib73","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3390\/cells10061552","article-title":"Impact of aldosterone on the failing myocardium: insights from mitochondria and adrenergic receptors signaling and function","volume":"10","author":"Guitart-Mampel","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.phrs.2021.105943_bib74","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/01.HYP.32.3.488","article-title":"Role of NADH\/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy","volume":"32","author":"Zafari","year":"1998","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.phrs.2021.105943_bib75","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/01.RES.86.5.494","article-title":"NAD(P)H oxidase: role in cardiovascular biology and disease","volume":"86","author":"Griendling","year":"2000","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.phrs.2021.105943_bib76","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/01.RES.0000033523.08033.16","article-title":"Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators","volume":"91","author":"Seshiah","year":"2002","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.phrs.2021.105943_bib77","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2012.4604","article-title":"Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease","volume":"19","author":"Dikalov","year":"2013","journal-title":"Antioxid. Redox Signal."},{"issue":"6","key":"10.1016\/j.phrs.2021.105943_bib78","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/01.ATV.0000069236.27911.68","article-title":"c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells","volume":"23","author":"Touyz","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105943_bib79","first-page":"573","article-title":"Angiotensin II blockade improves mitochondrial function in spontaneously hypertensive rats","volume":"51","author":"De Cavanagh","year":"2005","journal-title":"Cell Mol. Biol."},{"issue":"1\u20133","key":"10.1016\/j.phrs.2021.105943_bib80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0167-0115(00)00105-1","article-title":"Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerotic factors","volume":"90","author":"Dimmeler","year":"2000","journal-title":"Regul. Pept."},{"key":"10.1016\/j.phrs.2021.105943_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.566410","article-title":"Angiotensin II decreases endothelial nitric oxide synthase phosphorylation via AT1R Nox\/ROS\/PP2A pathway","volume":"11","author":"Ding","year":"2020","journal-title":"Front. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105943_bib82","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pharmthera.2013.07.004","article-title":"Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?","volume":"140","author":"Rochette","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"5\u20136","key":"10.1016\/j.phrs.2021.105943_bib83","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.vph.2012.02.004","article-title":"Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases","volume":"57","author":"Roe","year":"2012","journal-title":"Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105943_bib84","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157016112798829760","article-title":"The role of nitric oxide on endothelial function","volume":"10","author":"Tousoulis","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105943_bib85","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.ATV.20.3.645","article-title":"Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress","volume":"20","author":"Pueyo","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"15","key":"10.1016\/j.phrs.2021.105943_bib86","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/01.CIR.100.15.1646","article-title":"Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo","volume":"100","author":"Pastore","year":"1999","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.phrs.2021.105943_bib87","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/01.CIR.0000015603.84788.47","article-title":"Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway","volume":"105","author":"Kalra","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.phrs.2021.105943_bib88","first-page":"H786","article-title":"Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1 receptor and PKC activation","volume":"276","author":"Li","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105943_bib89","doi-asserted-by":"crossref","first-page":"C779","DOI":"10.1152\/ajpcell.00398.2003","article-title":"Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha","volume":"286","author":"Arenas","year":"2004","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105943_bib90","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41569-019-0227-9","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"16","author":"Basatemur","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105943_bib91","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/HYPERTENSIONAHA.118.11184","article-title":"PARP-1 (Poly[ADP-Ribose] polymerase 1) inhibition protects from ang II (angiotensin II)-induced abdominal aortic aneurysm in mice","volume":"72","author":"Liang","year":"2018","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.phrs.2021.105943_bib92","doi-asserted-by":"crossref","first-page":"H1660","DOI":"10.1152\/ajpheart.00028.2009","article-title":"ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice","volume":"296","author":"Cassis","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"28","key":"10.1016\/j.phrs.2021.105943_bib93","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.2174\/1381612821666150826093318","article-title":"Angiotensin II and abdominal aortic aneurysms: An update","volume":"21","author":"Liu","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.phrs.2021.105943_bib94","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/01.RES.80.1.139","article-title":"Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats","volume":"80","author":"Kudoh","year":"1997","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.phrs.2021.105943_bib95","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1254\/jjp.80.97","article-title":"Activation of mitogen-activated protein kinases in cardiovascular hypertrophy and remodeling","volume":"80","author":"Kim","year":"1999","journal-title":"Jpn J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105943_bib96","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3389\/fphys.2018.01860","article-title":"Upregulation of AT1 receptor mediates a pressor effect through ROS-SAPK\/JNK signaling in glutamatergic neurons of rostral ventrolateral medulla in rats with stress-induced hypertension","volume":"9","author":"Jiang","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.phrs.2021.105943_bib97","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nm1553","article-title":"Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure","volume":"13","author":"Lymperopoulos","year":"2007","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.phrs.2021.105943_bib98","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","article-title":"Adrenergic nervous system in heart failure: pathophysiology and therapy","volume":"113","author":"Lymperopoulos","year":"2013","journal-title":"Circ. Res."},{"issue":"5573","key":"10.1016\/j.phrs.2021.105943_bib99","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1126\/science.1071550","article-title":"G protein pathways","volume":"296","author":"Neves","year":"2002","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.phrs.2021.105943_bib100","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.jmb.2016.08.002","article-title":"Regulation, signaling, and physiological functions of g-proteins","volume":"428","author":"Syrovatkina","year":"2016","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105943_bib101","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.cell.2020.08.052","article-title":"A global map of G protein signaling regulation by RGS proteins","volume":"183","author":"Masuho","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.phrs.2021.105943_bib102","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1161\/HYPERTENSIONAHA.117.09757","article-title":"Angiotensin II type 1 receptor mechanoactivation involves RGS5 (regulator of G protein signaling 5) in skeletal muscle arteries: impaired trafficking of RGS5 in hypertension","volume":"70","author":"Hong","year":"2017","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.phrs.2021.105943_bib103","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/hr.2015.154","article-title":"The angiotensin II receptor antagonist, losartan, enhances regulator of G protein signaling 2 mRNA expression in vascular smooth muscle cells of Wistar rats","volume":"39","author":"Wu","year":"2016","journal-title":"Hypertens. Res."},{"issue":"6","key":"10.1016\/j.phrs.2021.105943_bib104","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1113\/expphysiol.2007.038240","article-title":"Regulator of G protein signalling 2 ameliorates angiotensin II-induced hypertension in mice","volume":"92","author":"Hercule","year":"2007","journal-title":"Exp. Physiol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105943_bib105","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/ijms20061396","article-title":"Deletion of osteopontin enhances \u03b2\u2082-adrenergic receptor-dependent anti-fibrotic signaling in cardiomyocytes","volume":"20","author":"Pollard","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2021.105943_bib106","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/cvr\/cvp285","article-title":"Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy","volume":"85","author":"Yue","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2021.105943_bib107","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13624","article-title":"Recent advances in pharmacological treatment of heart failure","author":"Iacoviello","year":"2021","journal-title":"Eur. J. Clin. Investig."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:59:38Z","timestamp":1750881578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821005272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":107,"alternative-id":["S1043661821005272"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105943","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular angiotensin II type 1 receptor biased signaling: Focus on non-Gq-, non-\u03b2arrestin-dependent signaling","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105943"}}